Arena Pharma (ARNA) Reports Complete Full Enrollment of Olorinab Phase 2 CAPTIVATE Trial for Abdominal Pain in IBS

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it has completed full enrollment of the Phase 2b CAPTIVATE trial evaluating olorinab, an investigational, oral, highly-selective, full agonist of the cannabinoid type 2 receptor (CB2), for the potential treatment of abdominal pain in irritable bowel syndrome (IBS). The trial enrolled 273 study participants at approximately 70 clinical sites across the United States, with a primary efficacy endpoint assessing improvement in the weekly Average Abdominal Pain Scale (AAPS) from baseline to week 12.

"With almost 80 percent of IBS patients experiencing recurring or continuous abdominal pain, we are pleased to announce our progress on the CAPTIVATE trial, evaluating olorinab as a potential non-opioid treatment option for patients and physicians," stated Chris Cabell, MD, MHS, FACC, Executive Vice President, Head of Research and Development, and Chief Medical Officer at Arena. "Olorinab is highly-selective and peripherally acting which we believe may translate into sustained pain relief with minimal drug abuse liability for patients across a broad range of conditions. We are extremely proud of the team that has worked diligently to enroll this trial, and we look forward to seeing topline Phase 2 data in early 2021."

You May Also Be Interested In

• Boeing (BA) Statement on U.S. Air Force Collaborative Combat Aircraft Announcement
• ADT Corp. (ADT) Appoints Jeffrey A. Likosar as Permanent CFO
• ADT Corp. (ADT) Names Jeff Likosar as Chief Financial Officer